Publications 2003
Original Papers
- Eich HT, Müller R-P, Schneeweiss A, Hansemann K, Semrau R, Willich N, Rübe C, Sehlen S, Hinkelbein M, Diehl V. Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 2004; 58 (3): 805-808.
- Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003; 21(19):3601-8. [FINAL ANALYSIS HD8]
- Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348(24):2386-95. [FINAL ANALYSIS HD9]
- Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003; 21(18):3440-6. Epub 2003 Mar 7.
- Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F, Driessen C, Rudiger T, Muller-Hermelink K, Diehl V, Engert A; German Hodgkin Lymphoma Study Group (GHSG). Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003; 101(2):420-4.
- Rüffer JU, Flechtner H, Tralls P, Josting A, Sieber M, Lathan B, Diehl V; German Hodgkin Lymphoma Study Group. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer. 2003;39(15):2179-86.
- Rueffer U, Sieber M, Stemberg M, Gossmann A, Josting A, Koch T, Grotenhermen F, Diehl V; German Hodgkin's Lymphoma Study Group (GHSG). Spleen involvement in Hodgkin's lymphoma: assessment and risk profile. Ann Hematol. 2003 Jul;82(7):390-6. Epub 2003 May 23.
- Sieber M, Bredenfeld H, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich HT, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclphosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: Results of a pilot study of the German Hodgkin‘s Lymphoma Study Group. J Clin Oncol 2003; 21 (9): 1734-1739.
Reviews
- Diehl V, von Wasielewski R. [25 years of the German Study Group of Hodgkin's Disease--a successful cooperation of pathologists and clinicians]. Verh Dtsch Ges Pathol. 2003; 87:58-65.
- Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough! J Clin Oncol. 2003; 21(4):583-5.
- Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003:225-47.
- Josting A, Diehl V. Current treatment strategies in early stage Hodgkin's disease. Curr Treat Options Oncol. 2003 Aug;4(4):297-305.
- Staak JO, Dietlein M, Engert A, Weihrauch MR, Schomäcker K, Fischer T, Eschner W, Borchmann P, Diehl V, Schicha H, Schnell R. Hodgkin’s lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin 2003; 42: 19-24.
- Weihrauch MR, Dietlein M, Schicha H, Diehl V, Tesch H. Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 2003; 44: 15-22.